Condition
Refractory Acute Myeloid Leukemia (AML)
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Not Yet Recruiting2
Active Not Recruiting1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07486726Phase 1Not Yet Recruiting
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
NCT06846606Phase 1Active Not Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06950034Phase 1Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT07347418Phase 1Not Yet RecruitingPrimary
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
NCT03787498Phase 1Completed
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Showing all 5 trials